Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Jun 15;126(12):2935-2937.
doi: 10.1002/cncr.32785. Epub 2020 Mar 10.

Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data

Affiliations
Comment

Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data

Celestia S Higano et al. Cancer. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST DISCLOSURES

Please see the conflicts of interest declarations in the manuscript.

Comment on

Similar articles

References

    1. Dores GM, Niu MT, Izurieta HS. Letter to the Editor: Potential understimation of cerebrovascular events in the Provenge Registry for the Observation, Collection, and Evaluation of Experience Data. Cancer. TBD. - PubMed
    1. Malarkey MA, Witten CM. April 29, 2010 Approval Letter - Provenge to Dendreon Corporation. In: Smith EC, editor. Bethesda, MD, 2010.
    1. Higano CS, Armstrong AJ, Sartor AO, et al. Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer. Cancer. 2019;125: 4172–4180. - PubMed
    1. Dendreon Data On File. PROCEED Registry Records. Seattle, WA: Dendreon Pharmaceuticals LLC.
    1. Dores GM, Bryant-Genevier M, Perez-Vilar S. Adverse Events Associated With the Use of Sipuleucel-T Reported to the US Food and Drug Administration’s Adverse Event Reporting System, 2010-2017Adverse Events Associated With Use of Sipuleucel-T Reported to FDAAdverse Events Associated With Use of Sipuleucel-T Reported to FDA. JAMA Network Open. 2019;2: e199249–e199249. - PMC - PubMed